Table 1.
Characteristic | No. = 957 | % |
---|---|---|
Age at diagnosis, years | ||
Mean | 64.5 | |
Range | 40.0–87.0 | |
Follow-up time, years | ||
Mean | 12.73 | |
Range | 0.28–32.6 | |
Prostate cancer-specific death | ||
No1 | 782 | 81.7 |
Yes | 98 | 10.2 |
Unknown2 | 77 | 8.0 |
Age at death, years | ||
Mean | 80.5 | |
Range | 54.0–99.0 | |
Stage at diagnosis | ||
Local | 623 | 65.1 |
Regional | 240 | 25.1 |
Distant | 27 | 2.8 |
Missing | 67 | 7.0 |
Gleason score at diagnosis | ||
≤ 6 | 561 | 58.6 |
7 (3+4) | 159 | 16.6 |
7 (4+3) | 45 | 4.7 |
8–10 | 80 | 8.4 |
Missing | 112 | 11.7 |
Diagnostic PSA level, ng/mL | ||
< 4.0 | 77 | 8.0 |
4–9.9 | 360 | 37.6 |
10–19.9 | 157 | 16.4 |
≥ 20 | 130 | 13.6 |
Missing | 233 | 24.3 |
Primary therapy | ||
Radical prostatectomy | 501 | 52.4 |
Radiation therapy | 256 | 26.8 |
Androgen deprivation | 75 | 7.8 |
Active surveillance | 21 | 2.2 |
Other | 18 | 1.9 |
Missing | 86 | 9.0 |
Includes men who died of other causes (n=258) or were alive at last follow-up (n=524).
Includes men who died but underlying cause of death is unknown.